STANFORD UNIVERSITY

Excellergy secured $70 million in Series A funding to develop first-in-class trifunctional Effector Cell Response Inhibitors (ECRIs) for allergic conditions.

China's NMPA has approved the Nerivio® REN wearable device, marking the first and only approval of Remote Electrical Neuromodulation technology for migraine treatment in the country.

Ridge Biotechnologies emerged from stealth with an oversubscribed $25 million seed financing led by Sutter Hill Ventures to advance AI-enabled enzyme and targeted drug design for precision medicines.

Stanford University has been awarded a double-digit million dollar NIH grant to conduct a Phase II trial of Tiprelestat for pulmonary arterial hypertension, with patient enrollment expected to begin in mid-2026.

4DMedical has received FDA 510(k) clearance for CT:VQ, the world's first non-contrast CT-based ventilation-perfusion imaging software that eliminates the need for radioactive tracers.

IgGenix has completed enrollment for its Phase 1 ACCELERATE Peanut study of IGNX001, a first-in-class monoclonal antibody therapy for peanut allergy prevention.

Foresight Diagnostics and Roche have entered a limited licensing agreement for PhasED-Seq technology, resolving litigation between the parties with all claims dismissed with prejudice.

Larkspur Biosciences announced the discovery of LRK-4189, a first-in-class degrader targeting the lipid kinase PIP4K2C for treating microsatellite stable colorectal cancer.

Multiply Labs' robotic biomanufacturing cluster achieves a 74% cost reduction in cell therapy production through collaborative robot arms from Universal Robots, as demonstrated in peer-reviewed studies with UCSF.

Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.